AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02551289 — intervention group
Intervention type: OTHER
Intervention: Gluten free diet
Description: Patients will follow a gluten free diet
Study NCT03467568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: 300mg sodium chloride will be provided in a capsule
Study NCT03467568 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
Study NCT03467568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule
Description: A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
Study NCT03467568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Twice during the morning a drink of 150ml of water will be consumed
Study NCT03467568 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: No water consumed
Description: No water will be consumed during the monring
Study NCT03467568 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: No water consumed
Description: No water will be consumed during the monring
Study NCT02386033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (ATV)
Description: After SRP, ATV gel was delivered subgingivally into the pocket
Study NCT02386033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study NCT04102293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual K-files
Description: manual instrumentation used in pulp therapy
Study NCT00249873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel (SR25990C)
Description: oral administration (tablets)
Study NCT00249873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration (tablets)
Study NCT01756989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, etoposide, celecoxib
Description: Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day.
Study NCT04521556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia with light general anesthesia
Description: Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ml and fentanyl 8.3 μg/ml.~Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
Study NCT04521556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative epidural analgesia
Description: Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
Study NCT04521556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1.~Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
Study NCT04521556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous intravenous analgesia
Description: Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
Study NCT03865030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: audiovestibular function
Description: Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness.
Study NCT00692575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving, education based telephone counseling
Description: Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
Study NCT00692575 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Intervention
Description: The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
Study NCT01518803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean-style breakfast
Description: The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
Study NCT01518803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western-style breakfast
Description: The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
Study NCT04121338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac ganglion block
Description: The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
Study NCT04121338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
Study NCT05882500 — intervention group
Intervention type: OTHER
Intervention: No intervention, observation
Study NCT02016443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
Study NCT02016443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
Study NCT02783612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose buddy application
Study NCT02718872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco cessation online training
Description: The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules.
Study NCT03920475 — intervention group
Intervention type: DRUG
Intervention: Sertraline or venlafaxine
Description: Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.
Study NCT03920475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immune parameters
Description: Serum was taken before, during an after treatment for measurement of different immune parameters.
Study NCT01348139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Inhaled via single inhaler device (SID)
Study NCT01348139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Inhaled via Turbuhaler inhaler
Study NCT01348139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AZD3199 Placebo
Description: Inhaled via Turbuhaler inhaler and SID
Study NCT01164202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: placebo 3cps/days 4 weeks over 6 during 1 year
Study NCT01164202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 3cps/days 4 weeks over 6 during 1 year
Study NCT01164202 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transarterial chemoembolization
Description: Chimioembolisation
Study NCT01164202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization
Description: Chimioembolisation
Study NCT00165503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00165503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Study NCT00165503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALIMTA
Study NCT01251042 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sangvia
Description: The Sangvia® Blood Salvage System used to collect blood intra-operatively.
Study NCT01251042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sangvia
Description: The Sangvia® Blood Salvage System used to collect blood intra-operatively.
Study NCT00145886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH
Description: Subjects will be treated with rhPTH for 12 months.
Study NCT01304797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302 Monotherapy
Description: Escalating doses of MM-302 as a single agent
Study NCT01304797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302 in combination with trastuzumab
Description: Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
Study NCT01304797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302 in combination with trastuzumab q3w
Description: Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
Study NCT01304797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302 in combination with trastuzumab and cyclophosphamide
Description: Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
Study NCT02317887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RS1 AAV Vector
Description: Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
Study NCT01278342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: 40 mg intramuscular (i.m.) every 28 days for 3 months
Study NCT01278342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandostatin LAR
Description: 40 mg intramuscular (i.m.) every 28 days for 3 months
Study NCT01278342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegvisomant
Description: Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
Study NCT02700854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% carbon-dioxide inhalation
Description: 5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE > -5 mmol/L in arterial blood gas samples
Study NCT01278342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline
Description: Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~1. st week: 0.25 mg twice a week (0.50 mg/week)~2. nd week: 0.50 mg/week twice a week (1 mg/week)~3. rd week: 0.50 mg four times a week (2 mg/week)~4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)
Study NCT02016768 — intervention group
Intervention type: PROCEDURE
Intervention: decompressive cervical surgery
Description: To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
Study NCT05102318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Pulp Capping
Description: Direct Pulp Capping
Study NCT05102318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy
Description: Partial Pulpotomy
Study NCT04478058 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live CBT
Description: Weekly in-person Cognitive Behavioural Therapy
Study NCT04478058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: Weekly online Cognitive Behavioural Therapy
Study NCT04110431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing
Description: Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold\<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).
Study NCT04110431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
Study NCT05733663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic procedure with duodenal biopsy
Description: * In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated.~* T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCRγδ+ IEL ≤8.5% (≤mean + 2SD) and CD3- IEL ≥10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCRγδ+ cells, and the coeliac lymphogram.
Study NCT04253340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bone mineral analyser
Description: high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
Study NCT01508988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 0.3 µg/mL both eyes on Day one
Study NCT01508988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 1 µg/mL both eyes on Day one
Study NCT01508988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 3 µg/mL both eyes on Day one
Study NCT01508988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 10 µg/mL both eyes on Day one
Study NCT01508988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 20 µg/mL both eyes on Day one
Study NCT01508988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Eye drops 30 µg/mL both eyes on Day one
Study NCT01508988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054
Description: Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
Study NCT00095979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT03555487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-choline PET
Description: 5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
Study NCT02485327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin SAR439065 Afrezza®
Description: Pharmaceutical form: dry powder~Route of administration: oral inhalation
Study NCT01235065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: type of laryngoscope
Description: Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
Study NCT05192265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimalarials, pyronaridine-artesunate
Description: The main interventions investigated are pyronaridine-artesunate granules or tablets (Pyramax™) manufactured by Shin Poong Pharmaceuticals, Seoul, Korea. Pyramax granules come in sachets with each containing 60mg of pyronaridine/20mg of artesunate while Pyramax tablets contain 180mg pyronaridine/60mg artesunate.
Study NCT05192265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antimalarials, Artemether + Lumefantrine
Description: Artemether-lumefantrine dispersible tablets (Coartem™, Novartis pharma) twice daily according to body weights. Each dispersible tablet of AL contains 20mg of artemether/120mg of lumefantrine).
Study NCT00231790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0634 50 mg
Description: one capsule orally, once daily in morning
Study NCT00231790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0634 125 mg
Description: one or three capsules orally, once daily in morning
Study NCT00231790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-0634
Description: one, two, three or four capsules orally once daily in morning
Study NCT02643641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
Study NCT02643641 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains aluminum hydroxide only
Study NCT04207905 — intervention group
Intervention type: OTHER
Intervention: Healthy Michigan Plan (HMP) coverage with work requirements
Description: For those who are not in the Exempt for Research Purposes group, to be eligible for HMP coverage beginning January 1, 2020, enrollees ages 19-62 must report 80 hours per calendar month of community engagement activities, such as employment, education, job training, job search activities, participation in substance use disorder (SUD) treatment, or community service.
Study NCT00965133 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Endurance training intervention
Description: High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
Study NCT05102318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy
Study NCT00059228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17beta Estradiol
Description: Alora 100 microgram per day by skin patch for 6 weeks.
Study NCT00059228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo skin patch for 6 weeks
Study NCT02945826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One injection of 68Ga-NOTA-AE105
Description: One injection of 68Ga-NOTA-AE105
Study NCT02945826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
Study NCT03983200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotating Magnetic Therapy
Description: Rotating Magnetic Therapy 30min, bid
Study NCT03983200 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mecobalamin
Description: mecobalamine 0.5mg,tid
Study NCT03983200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin
Description: mecobalamine 0.5mg,tid
Study NCT01682824 — intervention group
Intervention type: OTHER
Intervention: Nutritional Assessment
Description: Complete dietary intake assessment